Meeting
2017 ASCO Annual Meeting
Phase 3 KEYNOTE-361 trial: Pembrolizumab (pembro) with or without chemotherapy versus chemotherapy alone in advanced urothelial cancer.
Authors
Thomas Powles
Barts Cancer Institute, London, United Kingdom
Thomas Powles , Juergen E. Gschwend , Yohann Loriot , Joaquim Bellmunt , Lajos Geczi , Christof Vulsteke , Mahmoud Abdelsalam , Rustem Gafanov , Woo Kyun Bae , Janos Revesz , Yoshiaki Yamamoto , Urbano Anido , Wen-Pin Su , Mark T. Fleming , Maurice Markus , Dai Feng , Christian Heinrich Poehlein , Ajjai Alva
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary (Nonprostate) Cancer
Track
Genitourinary Cancer—Kidney and Bladder
Sub Track
Bladder Cancer
Clinical Trial Registration Number
NCT02853305
Citation
J Clin Oncol 35, 2017 (suppl; abstr TPS4590)
DOI
10.1200/JCO.2017.35.15_suppl.TPS4590
Abstract #
TPS4590
Poster Bd #
268a
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
KEYNOTE-C93/GOG-3064/ENGOT-en15: A phase 3, randomized, open-label study of first-line pembrolizumab versus platinum-doublet chemotherapy in mismatch repair deficient advanced or recurrent endometrial carcinoma.
First Author: Brian M. Slomovitz
Poster
2022 ASCO Genitourinary Cancers Symposium
Post hoc pooled analysis of first-line (1L) pembrolizumab (pembro) for advanced urothelial carcinoma (UC): Outcomes by response at week nine in KEYNOTE-052 and KEYNOTE-361.
First Author: Thomas Powles
Poster
2020 ASCO Virtual Scientific Program
Assessing the potential cost-effectiveness of the addition of atezolizumab to first-line platinum chemotherapy in advanced urothelial cancer: Implications for value-based pricing.
First Author: Ali Raza Khaki
Poster
2016 Genitourinary Cancers Symposium
TOUCAN: A randomised phase II trial of carboplatin and gemcitabine +/- vandetanib in first line treatment of advanced urothelial cell cancer in patients who are not suitable to receive cisplatin.
First Author: Robert J. Jones